-
Iran says defence capabilities 'never' up for negotiation
-
UN appeals for more support for flood-hit Mozambicans
-
Lijnders urges Man City to pile pressure on Arsenal in title race
-
Fulham sign Man City winger Oscar Bobb
-
Strasbourg's Argentine striker Panichelli sets sights on PSG, World Cup
-
Jesus 'made love': Colombian president irks Christians with steamy claim
-
IAEA board meets over Ukraine nuclear safety concerns
-
Eurozone growth beats 2025 forecasts despite Trump woes
-
Israel to partially reopen Gaza's Rafah crossing on Sunday
-
Dutch PM-elect Jetten says not yet time to talk to Putin
-
Social media fuels surge in UK men seeking testosterone jabs
-
Forest face Fenerbahce, Celtic draw Stuttgart in Europa League play-offs
-
US speed queen Vonn crashes at Crans-Montana, one week before Olympics
-
Trump nominates former US Fed official as next central bank chief
-
Alcaraz defends controversial timeout after beaten Zverev fumes
-
New Dutch government pledges ongoing Ukraine support
-
Newcastle still coping with fallout from Isak exit, says Howe
-
Chad, France eye economic cooperation as they reset strained ties
-
Real Madrid to play Benfica, PSG face Monaco in Champions League play-offs
-
Everton winger Grealish set to miss rest of season in World Cup blow
-
Trump brands Minneapolis nurse killed by federal agents an 'agitator'
-
Arteta focuses on the positives despite Arsenal stumble
-
Fijian Drua sign France international back Vakatawa
-
Kevin Warsh, a former Fed 'hawk' now in tune with Trump
-
Zverev rails at Alcaraz timeout in 'one of the best battles ever'
-
Turkey leads Iran diplomatic push as Trump softens strike threat
-
Zelensky backs energy ceasefire, Russia bombs Ukraine despite Trump intervention
-
'Superman' Li Ka-shing, Hong Kong billionaire behind Panama ports deal
-
Skiing great Lindsey Vonn crashes at Crans-Montana, one week before Olympics
-
Slot warns Liverpool 'can't afford mistakes' in top-four scrap
-
Paris show by late Martin Parr views his photos through political lens
-
'Believing' Alcaraz outlasts Zverev in epic to reach maiden Melbourne final
-
Artist chains up thrashing robot dog to expose AI fears
-
Alcaraz outlasts Zverev in epic to reach maiden Australian Open final
-
French PM forces final budget through parliament
-
French-Nigerian artists team up to craft future hits
-
Dutch watchdog launches Roblox probe over 'risks to children'
-
Trump brands Minneapolis nurse shot dead by federal agents an 'agitator'
-
Israel says killed 'three terrorists' in Gaza
-
After Trump-fueled brawls, Canada-US renew Olympic hockey rivalry
-
Eileen Gu - Olympic champion who bestrides rivals US, China
-
Trump, first lady attend premier of multimillion-dollar 'Melania' documentary
-
US Senate eyes funding deal vote as government shutdown looms
-
Cuddly Olympics mascot facing life or death struggle in the wild
-
UK schoolgirl game character Amelia co-opted by far-right
-
Anger as bid to ramp up Malaysia's football fortunes backfires
-
Panama court annuls Hong Kong firm's canal port concession
-
Pioneer African Olympic skier returns to Sarajevo slopes for documentary
-
Trump threatens tariffs on nations selling oil to Cuba
-
From fragile youngster to dominant star, Sabalenka chases more glory
Google unveils AI tool probing mysteries of human genome
Google unveiled an artificial intelligence tool Wednesday that its scientists said would help unravel the mysteries of the human genome -- and could one day lead to new treatments for diseases.
The deep learning model AlphaGenome was hailed by outside researchers as a "breakthrough" that would let scientists study and even simulate the roots of difficult-to-treat genetic diseases.
While the first complete map of the human genome in 2003 "gave us the book of life, reading it remained a challenge", Pushmeet Kohli, vice president of research at Google DeepMind, told journalists.
"We have the text," he said, which is a sequence of three billion nucleotide pairs represented by the letters A, T, C and G that make up DNA.
However "understanding the grammar of this genome -- what is encoded in our DNA and how it governs life -- is the next critical frontier for research," said Kohli, co-author of a new study in the journal Nature.
Only around two percent of our DNA contains instructions for making proteins, which are the molecules that build and run the body.
The other 98 percent was long dismissed as "junk DNA" as scientists struggled to understand what it was for.
However this "non-coding DNA" is now believed to act like a conductor, directing how genetic information works in each of our cells.
These sequences also contain many variants that have been associated with diseases. It is these sequences that AlphaGenome is aiming to understand.
- A million letters -
The project is just one part of Google's AI-powered scientific work, which also includes AlphaFold, the winner of 2024's chemistry Nobel.
AlphaGenome's model was trained on data from public projects that measured non-coding DNA across hundreds of different cell and tissue types in humans and mice.
The tool is able to analyse long DNA sequences then predict how each nucleotide pair will influence different biological processes within the cell.
This includes whether genes start and stop and how much RNA -- molecules which transmit genetic instructions inside cells -- is produced.
Other models already exist that have a similar aim. However they have to compromise, either by analysing far shorter DNA sequences or decreasing how detailed their predictions are, known as resolution.
DeepMind scientist and lead study author Ziga Avsec said that long sequences -- up to a million DNA letters long -- were "required to understand the full regulatory environment of a single gene".
And the high resolution of the model allows scientists to study the impact of genetic variants by comparing the differences between mutated and non-mutated sequences.
"AlphaGenome can accelerate our understanding of the genome by helping to map where the functional elements are and what their roles are on a molecular level," study co-author Natasha Latysheva said.
The model has already been tested by 3,000 scientists across 160 countries and is open for anyone to use for non-commercial reasons, Google said.
"We hope researchers will extend it with more data," Kohli added.
- 'Breakthrough' -
Ben Lehner, a researcher at Cambridge University who was not involved in developing AlphaGenome but did test it, said the model "does indeed perform very well".
"Identifying the precise differences in our genomes that make us more or less likely to develop thousands of diseases is a key step towards developing better therapeutics," he explained.
However AlphaGenome "is far from perfect and there is still a lot of work to do", he added.
"AI models are only as good as the data used to train them" and the existing data is not very suitable, he said.
Robert Goldstone, head of genomics at the UK's Francis Crick Institute, cautioned that AlphaGenome was "not a magic bullet for all biological questions".
This was partly because "gene expression is influenced by complex environmental factors that the model cannot see", he said.
However the tool still represented a "breakthrough" that would allow scientists to "study and simulate the genetic roots of complex disease", Goldstone added.
H.Thompson--AT